Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 3
1993 2
1994 1
1999 1
2000 1
2001 2
2002 3
2003 1
2004 2
2007 3
2008 4
2009 4
2010 2
2011 3
2012 6
2013 5
2014 3
2015 5
2016 3
2017 5
2018 5
2019 7
2020 6
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

72 results
Results by year
Filters applied: . Clear all
Page 1
SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission.
Corman VM, Rabenau HF, Adams O, Oberle D, Funk MB, Keller-Stanislawski B, Timm J, Drosten C, Ciesek S. Corman VM, et al. Among authors: keller stanislawski b. Transfusion. 2020 Jun;60(6):1119-1122. doi: 10.1111/trf.15841. Epub 2020 May 27. Transfusion. 2020. PMID: 32361996 Free PMC article.
Safety profile of rubella vaccine administered to pregnant women: A systematic review of pregnancy related adverse events following immunisation, including congenital rubella syndrome and congenital rubella infection in the foetus or infant.
Mangtani P, Evans SJW, Lange B, Oberle D, Smith J, Drechsel-Baeuerle U, Keller-Stanislawski B. Mangtani P, et al. Among authors: keller stanislawski b. Vaccine. 2020 Jan 29;38(5):963-978. doi: 10.1016/j.vaccine.2019.11.070. Epub 2019 Dec 12. Vaccine. 2020. PMID: 31839467 Review.
[Postvaccinal complications and management of suspected cases].
Oberle D, Mentzer D, Rocha F, Streit R, Weißer K, Keller-Stanislawski B. Oberle D, et al. Among authors: keller stanislawski b. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Apr;62(4):450-461. doi: 10.1007/s00103-019-02913-1. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019. PMID: 30820614 Review. German.
[Counterfeit medicines].
Keller-Stanislawski B, Paeschke N. Keller-Stanislawski B, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Nov;60(11):1185-1187. doi: 10.1007/s00103-017-2653-3. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017. PMID: 29067497 German. No abstract available.
Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.
Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C. Blankenbach K, et al. Among authors: keller stanislawski b. Neurology. 2019 May 7;92(19):e2232-e2239. doi: 10.1212/WNL.0000000000007451. Epub 2019 Apr 5. Neurology. 2019. PMID: 30952796
[Educational material as part of risk minimisation].
Heymans L, Huber M, Paeschke N, Palissa H, Keller-Stanislawski B. Heymans L, et al. Among authors: keller stanislawski b. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Sep;61(9):1088-1092. doi: 10.1007/s00103-018-2795-y. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018. PMID: 30083947 Review. German.
[Vaccine safety].
Weisser K, Barth I, Keller-Stanislawski B. Weisser K, et al. Among authors: keller stanislawski b. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Nov;52(11):1053-64. doi: 10.1007/s00103-009-0961-y. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009. PMID: 19771402 Review. German.
Aluminium from adjuvanted subcutaneous allergen immunotherapeutics in rats is mainly detected in bone.
Weisser K, Göen T, Oduro JD, Wangorsch G, Hanschmann KO, Keller-Stanislawski B. Weisser K, et al. Among authors: keller stanislawski b. Allergy. 2020 Jan;75(1):215-217. doi: 10.1111/all.13982. Epub 2019 Aug 1. Allergy. 2020. PMID: 31306489 No abstract available.
Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
Anton R, Haas M, Arlett P, Weise M, Balabanov P, Mazzaglia G, Prieto L, Keller-Stanislawski B, Raine J. Anton R, et al. Among authors: keller stanislawski b. Clin Pharmacol Ther. 2017 Aug;102(2):283-289. doi: 10.1002/cpt.604. Epub 2017 Jan 23. Clin Pharmacol Ther. 2017. PMID: 28001298 Review.
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma.
Ali S, Camarero J, Hennik PV, Bolstad B, Sommerfelt Grønvold M, Syvertsen C, Oddvar Strøm B, Ökvist M, Josephson F, Keller-Stanislawski B, Zafiropoulos N, Pean E, Bergh J, da Rocha Dias S, Pignatti F. Ali S, et al. Among authors: keller stanislawski b. ESMO Open. 2020 Nov;5(6):e000798. doi: 10.1136/esmoopen-2020-000798. ESMO Open. 2020. PMID: 33188050 Free PMC article. Review.
72 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback